Enhancing Cisplatin Effectiveness with Retinoic Acid in Ovarian Cancer Cells
Author Information
Author(s): MJ Caliaro, P Vitaux, C Lafon, I Lochon, A N6hm6, A Valette, P Canal, R Bugat, S Jozan
Primary Institution: Centre Claudius Regaud, Toulouse, France
Hypothesis
Can all-trans retinoic acid (ATRA) enhance the cytotoxicity of cisplatin in human ovarian carcinoma cell lines?
Conclusion
ATRA enhances the cytotoxicity of cisplatin in ovarian carcinoma cell lines that are sensitive to ATRA.
Supporting Evidence
- ATRA increased the sensitivity of NIHOVCAR3 and OVCCR1 cells to cisplatin.
- Synergy between ATRA and cisplatin was observed only in ATRA-sensitive cell lines.
- ATRA did not increase cellular platinum content in the tested cell lines.
- Decreased glutathione S-transferase activity was associated with increased cisplatin cytotoxicity.
Takeaway
This study shows that a vitamin A derivative can make a cancer drug work better in certain types of ovarian cancer cells.
Methodology
The study used clonogenic assays to measure the cytotoxicity of cisplatin in various ovarian carcinoma cell lines pretreated with ATRA.
Limitations
The study primarily focused on in vitro cell lines, which may not fully represent in vivo conditions.
Participant Demographics
Human ovarian carcinoma cell lines, including both ATRA-sensitive and ATRA-insensitive types.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website